In this segment of the Motley Fool's Market Check-Up, Fool health-care analyst David Williamson takes investors through some of the biggest stories affecting Big Pharma, biotech stocks, and the health insurance industry today.
Bristol-Myers Squibb (BMY +0.67%) has announced it will be divesting itself of its joint diabetes franchise that it held with AstraZeneca (AZN +0.00%), selling its portion back to AZN for $2.7 billion, plus a milestone payment of $700 million if the sodium-glucose transport protein SGLT2 drug Forxega, focused on the treatment of diabetes, is approved. David discusses the likelihood of Forxega approval, and what this could mean both for Bristol-Myers Squibb, and for AstraZeneca, as well as why it is important as an investor to be thinking long-term about Bristol-Myers when looking at this deal today.
